Lundbeck has moved to expand its reach in the neurology market with the acquisition of Abide Therapeutics, a company focused on targeting enzymes of the serine hydrolase class, for a deal value of up to US$400 M. With the acquisition, Lundbeck gains access to Abide’s pipeline of serine hydrolase inhibitors, including lead candidate, ABX-1431, a first-in class inhibitor of monoacylglycerol lipase that modulates the endocannabinoid system. The deal follows the loss of exclusivity for Onfi® (clobazam) as well asa series of pipeline setbacks for Lundbeck.